1. Insights
  2. News
  3. Media Mentions

Brian Pomper Quoted by Chemical & Engineering News on TPP IP Protection Plan for Biologics

February 29, 2016

Reading Time : 1 min
Jump to
View People Mentioned in This NewsView Related Services, Sectors, and Regions

Contact:

Jacinta O'Shea-Ramdeholl

Director of Communications

Send Email
+1 212.407.3080

Sarah Richmond

Senior Communications Manager

Send Email
+1 202.416.5150

Chemical & Engineering News, for its article “Trans-Pacific trade pact faces rocky road,” quoted Akin Gump public law and policy partner Brian Pomper on the Trans-Pacific Partnership (TPP)’s plan for biologic medicines regarding intellectual property protection.

According to the article, currently, nations within the TPP have a variety of different approaches regarding the length of market protections for biologics ranging from 12 years to having no protection at all. Negotiators recently agreed upon a deal that allows the U.S. to keep its current 12-year standard while requiring other nations to adopt a five- to eight-year protection period—a decision that has been met with opposition by several of the TPP countries.

Of the deal, Pomper said, “there is no way TPP will pass without some significant accommodations on the biopharmaceutical side.”

Share This Insight

Related Services, Sectors, and Regions

© 2024 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.